Background and Objectives: Shortages of dermatologists create significant barriers to care, particularly for inflammatory and history-dependent conditions where image-only artificial intelligence (AI) classifiers have limited applicability. Current teledermatology solutions largely focus on single-task, morphology-based neoplasm classifiers, leaving the vast majority of dermatologic presentations underserved. This study evaluated the diagnostic accuracy and management plan quality of Dermflow (Prava Medical, Delaware, USA), a proprietary dermatology-focused Multimodal Image-and-Data Assistant (MIDA) that autonomously gathers dermatology-specific history, integrates data with patient-submitted images, and outputs structured differential diagnoses and management summaries. Materials and Methods: Two AI systems, Dermflow and Claude Sonnet 4 (Claude, a leading vision–language model), analyzed 87 clinical images from the Skin Condition Image Network and Diverse Dermatology Images databases, representing 10 inflammatory dermatoses and 9 neoplastic conditions stratified across Fitzpatrick Skin Tone (FST) categories (I–II, III–IV, V–VI). For the diagnostic comparison, Dermflow received images and autonomously gathered clinical history, while Claude received identical images without history. For the management plan comparison, both systems received the correct diagnosis and the clinical histories gathered by Dermflow. The primary outcome was diagnostic accuracy. The secondary outcome was management plan quality, assessed by two blinded dermatologists across eight clinical dimensions using 5-point Likert scales. Chi-square tests compared diagnostic accuracy between models; t-tests and ANOVA compared management quality scores. Results: Dermflow achieved markedly superior diagnostic accuracy compared to Claude (86.2% vs. 24.1%, p < 0.001). Both models maintained consistent diagnostic performance across FST categories without significant within-model differences (Dermflow p = 0.924; Claude p = 0.828). Management plan quality showed no significant overall differences between models. However, composite management quality scores declined significantly for darker skin tones across both systems: Dermflow scored 4.20 (FST I–II), 3.99 (FST III–IV), and 3.47 (FST V–VI); Claude scored 4.35, 3.97, and 3.44, respectively (p < 0.001 for most pairwise FST comparisons within each model). Conclusions: Multimodal AI integrating targeted history with image analysis achieves substantially higher diagnostic accuracy than image-only approaches across both inflammatory and neoplastic dermatologic conditions. Autonomous history gathering addresses fundamental limitations of morphology-only classifiers and enables scalable, patient-facing triage across the full spectrum of dermatologic disease. However, both models demonstrated reduced management plan quality for darker skin tones despite receiving the correct diagnosis, suggesting persistent training data limitations that require targeted bias-mitigation strategies beyond domain-specific instruction.
Mijares et al. (Thu,) studied this question.